United States Tumor Necrosis Factor Inhibitors Drug Market Report 2018

March 2018 | 123 pages | ID: U5EBAA936CEEN
QYResearch

Abstracts

In this report, the United States Tumor Necrosis Factor Inhibitors Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Tumor Necrosis Factor Inhibitors Drug in these regions, from 2013 to 2025 (forecast).

United States Tumor Necrosis Factor Inhibitors Drug market competition by top manufacturers/players, with Tumor Necrosis Factor Inhibitors Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Apogenix
• AryoGen Biopharma
• Bionovis
• CASI Pharmaceuticals
• Celltrion
• Celgene Corporation
• Delenex Therapeutics
• Dexa Medica
• EPIRUS Biopharmaceuticals
• Janssen Biotech
• GlaxoSmithKline
• HanAll Biopharma
• Intas Pharmaceuticals
• LEO Pharma
• LG Life Sciences
• MedImmune
• Momenta Pharmaceuticals
• Novartis
• PROBIOMED
• Reliance Life Sciences
• Sandoz
• Samsung Bioepis
• Sanofi-Aventis
• Shanghai CP Guojian Pharmaceutical
• Shanghai Pharmaceuticals
• Simcere Pharmaceutical
• Toyama Chemical
• Tsumura
• UCB
• Zydus Cadila

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Cimzia (Certolizumab Pegol)
• Enbrel (Etanercept)
• Humira ( Adalimumab)
• Otezla (Apremilast)
• Remicade (Infliximab)
• Simponi (Golimumab)

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Clinic
• Hospital
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Tumor Necrosis Factor Inhibitors Drug Market Report 2018

1 TUMOR NECROSIS FACTOR INHIBITORS DRUG OVERVIEW

1.1 Product Overview and Scope of Tumor Necrosis Factor Inhibitors Drug
1.2 Classification of Tumor Necrosis Factor Inhibitors Drug by Product Category
  1.2.1 United States Tumor Necrosis Factor Inhibitors Drug Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Tumor Necrosis Factor Inhibitors Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 Cimzia (Certolizumab Pegol)
  1.2.4 Enbrel (Etanercept)
  1.2.5 Humira ( Adalimumab)
  1.2.6 Otezla (Apremilast)
  1.2.7 Remicade (Infliximab)
  1.2.8 Simponi (Golimumab)
1.3 United States Tumor Necrosis Factor Inhibitors Drug Market by Application/End Users
  1.3.1 United States Tumor Necrosis Factor Inhibitors Drug Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Clinic
  1.3.3 Hospital
  1.3.4 Others
1.4 United States Tumor Necrosis Factor Inhibitors Drug Market by Region
  1.4.1 United States Tumor Necrosis Factor Inhibitors Drug Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2013-2025)
  1.4.3 Southwest Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2013-2025)
  1.4.5 New England Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2013-2025)
  1.4.6 The South Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2013-2025)
  1.4.7 The Midwest Tumor Necrosis Factor Inhibitors Drug Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Tumor Necrosis Factor Inhibitors Drug (2013-2025)
  1.5.1 United States Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2013-2025)
  1.5.2 United States Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2013-2025)

2 UNITED STATES TUMOR NECROSIS FACTOR INHIBITORS DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Tumor Necrosis Factor Inhibitors Drug Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Tumor Necrosis Factor Inhibitors Drug Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Tumor Necrosis Factor Inhibitors Drug Average Price by Players/Suppliers (2013-2018)
2.4 United States Tumor Necrosis Factor Inhibitors Drug Market Competitive Situation and Trends
  2.4.1 United States Tumor Necrosis Factor Inhibitors Drug Market Concentration Rate
  2.4.2 United States Tumor Necrosis Factor Inhibitors Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Tumor Necrosis Factor Inhibitors Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES TUMOR NECROSIS FACTOR INHIBITORS DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Region (2013-2018)
3.2 United States Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Region (2013-2018)
3.3 United States Tumor Necrosis Factor Inhibitors Drug Price by Region (2013-2018)

4 UNITED STATES TUMOR NECROSIS FACTOR INHIBITORS DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Type (2013-2018)
4.3 United States Tumor Necrosis Factor Inhibitors Drug Price by Type (2013-2018)
4.4 United States Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Type (2013-2018)

5 UNITED STATES TUMOR NECROSIS FACTOR INHIBITORS DRUG SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Application (2013-2018)
5.2 United States Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES TUMOR NECROSIS FACTOR INHIBITORS DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Apogenix
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 AryoGen Biopharma
  6.2.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Bionovis
  6.3.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 CASI Pharmaceuticals
  6.4.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Celltrion
  6.5.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Celgene Corporation
  6.6.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview
6.7 Delenex Therapeutics
  6.7.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.7.4 Main Business/Business Overview
6.8 Dexa Medica
  6.8.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.8.4 Main Business/Business Overview
6.9 EPIRUS Biopharmaceuticals
  6.9.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.9.4 Main Business/Business Overview
6.10 Janssen Biotech
  6.10.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.10.4 Main Business/Business Overview
6.11 GlaxoSmithKline
6.12 HanAll Biopharma
6.13 Intas Pharmaceuticals
6.14 LEO Pharma
6.15 LG Life Sciences
6.16 MedImmune
6.17 Momenta Pharmaceuticals
6.18 Novartis
6.19 PROBIOMED
6.20 Reliance Life Sciences
6.21 Sandoz
6.22 Samsung Bioepis
6.23 Sanofi-Aventis
6.24 Shanghai CP Guojian Pharmaceutical
6.25 Shanghai Pharmaceuticals
6.26 Simcere Pharmaceutical
6.27 Toyama Chemical
6.28 Tsumura
6.29 UCB
6.30 Zydus Cadila

7 TUMOR NECROSIS FACTOR INHIBITORS DRUG MANUFACTURING COST ANALYSIS

7.1 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Tumor Necrosis Factor Inhibitors Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Tumor Necrosis Factor Inhibitors Drug Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES TUMOR NECROSIS FACTOR INHIBITORS DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Tumor Necrosis Factor Inhibitors Drug Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Tumor Necrosis Factor Inhibitors Drug Sales Volume Forecast by Type (2018-2025)
11.3 United States Tumor Necrosis Factor Inhibitors Drug Sales Volume Forecast by Application (2018-2025)
11.4 United States Tumor Necrosis Factor Inhibitors Drug Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Tumor Necrosis Factor Inhibitors Drug
Figure United States Tumor Necrosis Factor Inhibitors Drug Market Size (K Pcs) by Type (2013-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Volume Market Share by Type (Product Category) in 2017
Figure Cimzia (Certolizumab Pegol) Product Picture
Figure Enbrel (Etanercept) Product Picture
Figure Humira ( Adalimumab) Product Picture
Figure Otezla (Apremilast) Product Picture
Figure Remicade (Infliximab) Product Picture
Figure Simponi (Golimumab) Product Picture
Figure United States Tumor Necrosis Factor Inhibitors Drug Market Size (K Pcs) by Application (2013-2025)
Figure United States Sales Market Share of Tumor Necrosis Factor Inhibitors Drug by Application in 2017
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Tumor Necrosis Factor Inhibitors Drug Market Size (Million USD) by Region (2013-2025)
Figure The West Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) and Growth Rate (2013-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Market Major Players Product Sales Volume (K Pcs) (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) of Key Players/Suppliers (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Tumor Necrosis Factor Inhibitors Drug Sales Share by Players/Suppliers
Figure 2017 United States Tumor Necrosis Factor Inhibitors Drug Sales Share by Players/Suppliers
Figure United States Tumor Necrosis Factor Inhibitors Drug Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Tumor Necrosis Factor Inhibitors Drug Revenue Share by Players/Suppliers
Figure 2017 United States Tumor Necrosis Factor Inhibitors Drug Revenue Share by Players/Suppliers
Table United States Market Tumor Necrosis Factor Inhibitors Drug Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)
Figure United States Market Tumor Necrosis Factor Inhibitors Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2017
Figure United States Tumor Necrosis Factor Inhibitors Drug Market Share of Top 3 Players/Suppliers
Figure United States Tumor Necrosis Factor Inhibitors Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Tumor Necrosis Factor Inhibitors Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Tumor Necrosis Factor Inhibitors Drug Product Category
Table United States Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Region (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Share by Region (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Share by Region (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region in 2017
Table United States Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Revenue Share by Region (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region in 2017
Table United States Tumor Necrosis Factor Inhibitors Drug Price (USD/Pcs) by Region (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Type (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Share by Type (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Share by Type (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2017
Table United States Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Tumor Necrosis Factor Inhibitors Drug by Type (2013-2018)
Figure Revenue Market Share of Tumor Necrosis Factor Inhibitors Drug by Type in 2017
Table United States Tumor Necrosis Factor Inhibitors Drug Price (USD/Pcs) by Types (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Type (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Application (2013-2018)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2017
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Application (2013-2018)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Application (2013-2018)
Table Apogenix Basic Information List
Table Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Apogenix Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure Apogenix Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure Apogenix Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table AryoGen Biopharma Basic Information List
Table AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table Bionovis Basic Information List
Table Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Bionovis Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure Bionovis Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure Bionovis Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table CASI Pharmaceuticals Basic Information List
Table CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table Celltrion Basic Information List
Table Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Celltrion Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure Celltrion Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure Celltrion Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table Celgene Corporation Basic Information List
Table Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table Delenex Therapeutics Basic Information List
Table Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table Dexa Medica Basic Information List
Table Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure Dexa Medica Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table EPIRUS Biopharmaceuticals Basic Information List
Table EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table Janssen Biotech Basic Information List
Table Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2013-2018)
Figure Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales Market Share in United States (2013-2018)
Figure Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Revenue Market Share in United States (2013-2018)
Table GlaxoSmithKline Basic Information List
Table HanAll Biopharma Basic Information List
Table Intas Pharmaceuticals Basic Information List
Table LEO Pharma Basic Information List
Table LG Life Sciences Basic Information List
Table MedImmune Basic Information List
Table Momenta Pharmaceuticals Basic Information List
Table Novartis Basic Information List
Table PROBIOMED Basic Information List
Table Reliance Life Sciences Basic Information List
Table Sandoz Basic Information List
Table Samsung Bioepis Basic Information List
Table Sanofi-Aventis Basic Information List
Table Shanghai CP Guojian Pharmaceutical Basic Information List
Table Shanghai Pharmaceuticals Basic Information List
Table Simcere Pharmaceutical Basic Information List
Table Toyama Chemical Basic Information List
Table Tsumura Basic Information List
Table UCB Basic Information List
Table Zydus Cadila Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Tumor Necrosis Factor Inhibitors Drug
Figure Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug
Figure Tumor Necrosis Factor Inhibitors Drug Industrial Chain Analysis
Table Raw Materials Sources of Tumor Necrosis Factor Inhibitors Drug Major Players/Suppliers in 2017
Table Major Buyers of Tumor Necrosis Factor Inhibitors Drug
Table Distributors/Traders List
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Price (USD/Pcs) Trend Forecast (2018-2025)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Volume (K Pcs) Forecast by Type in 2025
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Volume (K Pcs) Forecast by Application in 2025
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Volume (K Pcs) Forecast by Region (2018-2025)
Table United States Tumor Necrosis Factor Inhibitors Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitors Drug Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources